LA JOLLA, Calif.--(BUSINESS WIRE)--Sept. 8, 2006--Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products, today announced that it has obtained an exclusive option to evaluate and license a family of patents and patent applications controlled by AROS Applied Biotechnology ("AROS") of Denmark. Under the terms of the agreement, Stratagene will have the right to evaluate and exclusively license the rights to certain gene groups that have been shown to have predictive capabilities for certain cancers. Financial terms of the agreement were not disclosed.
